Arcutis Biotherapeutics CMO sells 955 shares

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett reported selling 955 shares of common stock on 2026-08-03 at a weighted-average price of $26.1168 per share, in multiple trades between $25.72 and $26.69.

Rhea-AI Filing Summary

Arcutis Biotherapeutics EVP and Chief Medical Officer Patrick Burnett reported selling 955 shares of common stock on 2026-08-03 at a weighted-average price of $26.1168 per share, in multiple trades between $25.72 and $26.69. Footnotes state the sale was solely to cover tax withholding obligations arising from vesting Restricted Stock Units and was effected pursuant to a Rule 10b5-1 trading plan. After this transaction, Burnett directly owns 119,289 shares of Arcutis common stock.

Insider Trade Summary 10b5-1

Net Seller: 955 shares

Net Sell 1 txn

Insider Burnett Patrick

Role See Remarks

Sold 955 shs ($25K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	955	$26.1168	$25K

Holdings After Transaction: Common Stock — 119,289 shares (Direct)

Footnotes (2)

1. F1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Key Figures

Shares sold: 955 shares Weighted-average sale price: $26.1168 per share Sale price range: $25.72 to $26.69 per share +1 more

4 metrics

Shares sold 955 shares Common stock sold on 2026-08-03 to cover tax withholding obligations

Weighted-average sale price $26.1168 per share Average price for the 955 shares of common stock sold

Sale price range $25.72 to $26.69 per share Range of prices for multiple sale transactions aggregated in the Form 4

Shares owned after transaction 119,289 shares Directly owned Arcutis common stock following the reported sale

Key Terms

Restricted Stock Units, weighted average sale price, tax withholding obligations

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcutis Biotherapeutics (ARQT) report for Patrick Burnett?

Arcutis reported that EVP and CMO Patrick Burnett sold 955 shares of common stock on 2026-08-03. The weighted-average sale price was $26.1168 per share, executed in multiple trades between $25.72 and $26.69.

Why did Patrick Burnett sell 955 ARQT shares in this Form 4 filing?

The filing states the 955-share sale was solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units. This indicates the transaction was related to equity compensation rather than a discretionary open-market sale for personal liquidity.

Was Patrick Burnett’s ARQT stock sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 indicates the transaction was effected under a Rule 10b5-1 trading plan. Such plans pre-establish trading parameters, so the timing of the 955-share sale is governed by the plan’s terms rather than day-to-day trading discretion.

What price did Patrick Burnett receive for the 955 ARQT shares sold?

The reported weighted-average sale price was $26.1168 per share for the 955 shares sold. Footnotes explain the shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, and detailed breakdowns are available upon request.

How many Arcutis Biotherapeutics (ARQT) shares does Patrick Burnett hold after this sale?

Following the reported transaction, Patrick Burnett directly owns 119,289 shares of Arcutis common stock. This post-transaction holding reflects his position after selling 955 shares to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 09:42 PM Accepted by SEC EDGAR 08/05/2026 - 09:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		955	D	$26.1168(2)	119,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's title: EVP, Chief Medical Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)